Eupraxia Pharmaceuticals (EPRX) Non-Current Assets (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Non-Current Assets data on file, last reported at $3.2 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 415.07% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $6.0 million, a 191.38% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 107.93% from the prior year.
• Non-Current Assets for Q1 2026 stood at $3.2 million, up from $1.1 million in the prior quarter.
• Over the last five years, Non-Current Assets for EPRX reached as high as $3.2 million in Q1 2026 and fell as low as $420425.0 in Q1 2024.
• Historically, Non-Current Assets has averaged $860854.7 across 5 years, with a median of $533242.0 in 2022.
• Across the five-year window, Non-Current Assets declined 13.14% in 2023 and soared 415.07% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $533242.0 in 2022, then retreated by 13.14% to $463151.0 in 2023, then grew by 9.18% to $505677.0 in 2024, then soared by 107.93% to $1.1 million in 2025, then jumped by 207.03% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $3.2 million in Q1 2026, $1.1 million in Q4 2025, and $949192.0 in Q3 2025.